Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

Inclusion Criteria

• •Main criteria:
• •1. Natural, surgically- or treatment-induced postmenopausal women (non hysterectomized or hysterectomized) with breast cancer (stage 1 or 2) who is currently under treatment with an aromatase inhibitor and will remain on that treatment for the duration of the study.
• •2. Women between 30 and 80 years of age
• •3. Women having ≤5% of superficial cells on vaginal smear at baseline
• •4. Women having a vaginal pH above 5 at baseline
• •5. Women who have self-identified moderate or severe symptom(s) of vaginal atrophy